Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price & Analysis
Arrowhead Pharmaceuticals, Inc. (ARWR) closed at USD 58.5 on Thursday, October 15, 2026, up 0.22% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 58.37; the Oct 15, 2026 session ranged USD 57.4–59.4 on volume of 2,009,448 shares. Market capitalization is $8.26B, with a 52-week range of USD 36.57–95.49 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ARWR.md
Key facts (ARWR)
- Last four reported quarters (through Jun 30, 2026): revenue $669M, net income -$320M (-47.8% margin), free cash flow -$75.1M (SEC filings).
- 1 of 80 tracked superinvestors hold ARWR (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 1.80 on a 1–5 scale) (15 analysts), mean target USD 107.36 (range 74–126).
- Total return with dividends: 1Y +50.1% vs S&P 500 +18.1%; 5Y -11.6% vs S&P 500 +85.1%.
- Next earnings: 2026-11-24, EPS estimate USD -1.5, revenue estimate $60.4M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ARWR)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $138M | $243M | $241M | $3.6M | $829M | $669M |
| Operating income | -$149M | -$179M | -$205M | -$601M | $98.3M | -$226M |
| Net income | -$141M | -$176M | -$205M | -$599M | -$1.6M | -$320M |
| EPS (diluted) | -$1.36 | -$1.67 | -$1.92 | -$5.00 | -$0.01 | — |
| Free cash flow | $148M | -$189M | -$331M | -$604M | $157M | -$75.1M |
| Operating margin | -107.8% | -73.4% | -85.2% | -16927.1% | 11.9% | -33.8% |
| Net margin | -101.9% | -72.4% | -85.3% | -16882.4% | -0.2% | -47.8% |
| Revenue growth | +57.2% | +75.9% | -1.0% | -98.5% | +23258.2% | — |
| Cash + short-term investments | $311M | $108M | $404M | $681M | $919M | — |
Fiscal years end Sep. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ARWR)
P/S 12.3x · P/B 17.8x · FCF yield -0.91% · Earnings yield -3.87%
Superinvestors (SEC 13F-HR, Q2 2026) (ARWR)
1 of 80 tracked investors hold ARWR. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Polen Capital | Polen Capital Management | <0.01% | $539K | New position |
Analysts (ARWR)
Consensus Buy (mean 1.80 on a 1–5 scale), 15 analysts; mean target USD 107.36 (low 74, high 126).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | Chardan Capital | Maintained | Buy | $115 |
| 2026-10-15 | HC Wainwright & Co. | Reiterated | Buy | $120 |
| 2026-09-08 | Citigroup | Initiated | Buy | $108 |
| 2026-09-01 | HC Wainwright & Co. | Reiterated | Buy | $120 |
| 2026-08-31 | Chardan Capital | Maintained | Buy | $115 |
| 2026-08-31 | RBC Capital | Reiterated | Outperform | $100 |
| 2026-08-06 | HC Wainwright & Co. | Target raised | Buy | $115 → $120 |
| 2026-07-30 | B. Riley Securities | Target raised | Buy | $101 → $123 |
| 2026-07-27 | HC Wainwright & Co. | Target raised | Buy | $100 → $115 |
| 2026-07-23 | Morgan Stanley | Target raised | Overweight | $100 → $120 |
| 2026-07-23 | Piper Sandler | Target raised | Overweight | $110 → $126 |
| 2026-07-22 | Chardan Capital | Target raised | Buy | $90 → $115 |
Total return (dividends reinvested) (ARWR)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +50.1% | -11.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +50.3% | -2.4% |
| Volatility (annualized) | 60.7% | 61.6% |
| Max drawdown | -35.1% (Aug 2026→Oct 2026) | -86.8% (Nov 2021→Mar 2025) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 58.5 |
|---|---|
| Change | ▲ 0.22% (up) |
| Previous Close | USD 58.37 |
| Open | USD 58.55 |
| Day Range | USD 57.4 – 59.4 |
| 52-Week Range | USD 36.57 – 95.49 |
| Volume | 2,009,448 shares |
| Market Cap | $8.26B |
| Exchange | NMS |
Technical Analysis (ARWR)
Nexqual's technical model rates ARWR "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.76 (oversold) |
| vs SMA50 | Below (USD 76.15) |
| MACD | -4.82 (negative) |
Analyst Ratings (ARWR)
Wall Street analysts rate ARWR "Buy" based on 15 analysts, with a mean price target of USD 107.36 (range USD 74–126), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 107.36 |
| High Target | USD 126 |
| Low Target | USD 74 |
| Buy / Hold / Sell | 14 / 1 / 0 |
Earnings (ARWR)
| Next Earnings Date | 2026-11-24 |
|---|---|
| EPS Estimate | USD -1.5 |
| Revenue Estimate | $60.44M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.36 vs est -1.23 ▼ miss |
| 2026-03-31 | USD -0.93 vs est -1.11 ▲ beat |
| 2025-12-31 | USD 0.22 vs est -0.37 ▲ beat |
| 2025-09-30 | USD -0.18 vs est -0.16 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (ARWR)
| Total Revenue | $669.49M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +171.00% |
| Gross Margin | +100.00% |
| Operating Margin | -226.03% |
| Profit Margin | -47.79% |
| ROE | -55.21% |
| Debt / Equity | 2.96 |
| Current Ratio | 5.9 |
| Total Cash | $1.60B |
| Total Debt | $1.38B |
| Free Cash Flow (fiscal year ended Sep 2025, SEC 10-K) | $156.89M (18.9% of revenue) |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (ARWR)
Nexqual rates Arrowhead Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $1.60B cash vs $1.38B debt, net cash position |
| Cash Flow | Strong — FCF $157M (FY ended Sep 2025, 10-K), 19% margin |
| Efficiency | Critical — ROE -55%, ROA -8.1% |
Ownership (ARWR)
| Insider Ownership | +3.66% |
|---|---|
| Institutional Ownership | +85.41% |
| Shares Outstanding | 141.25M |
| Float | 122.45M |
| Short % of Float | +10.60% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (ARWR)
Arrowhead Pharmaceuticals, Inc. is led by Christopher R. Anzalone (age 56), Chairman, CEO & President, per Nexqual as of October 16, 2026 at 05:22 UTC.
| Chairman, CEO & President | Christopher R. Anzalone (age 56) |
|---|---|
| Chief Financial Officer | Daniel J. Apel (age 59) |
| COO & Secretary | Patrick O'Brien J.D., PharmD (age 61) |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | Mark M. Davis |
| Chief Scientific Officer | Tao Pei |
Major Backers & Investors (ARWR)
Notable institutional backers of Arrowhead Pharmaceuticals, Inc. include Avoro Capital Advisors LLC, FMR, LLC, Invesco, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Avoro Capital Advisors LLC | 8.06% |
| FMR, LLC | 5.71% |
| Invesco | 4.03% |
| NORGES BANK | 2.77% |
| Fred Alger Management, LLC | 2.34% |
| Fidelity | 1.85% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.45% |
| BlackRock | 14.73% |
| State Street | 6.05% |
| Geode Capital | 2.51% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ABVX | Abivax SA | USD 92.38 | ▲ 7.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 161.79 | ▲ 3.5% |
| TGTX | TG Therapeutics, Inc. | USD 56 | ▲ 3.05% |
| PTGX | Protagonist Therapeutics, Inc. | USD 136.55 | ▼ 1.4% |
| CYTK | Cytokinetics, Incorporated | USD 63.92 | ▲ 3.73% |
| CAI | Caris Life Sciences, Inc. | USD 31.76 | ▲ 7.55% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt